Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.01 per share a year ago. These ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Shares of the company surged 23% in premarket trading after the company swung to profit in the first quarter, helped by reduced costs tied to the development and sale of its COVID-19 vaccine, its only ...

Shares of the company rose 8.74% to $6.47 in premarket trading. Novavax, whose protein-based shot uses an older technology, missed out on the pandemic vaccine windfall – enjoyed by rivals Moderna and ...